Free Trial
NASDAQ:CLYM

Climb Bio (CLYM) Stock Price, News & Analysis

Climb Bio logo
$2.38 +0.19 (+8.68%)
As of 08/22/2025 04:00 PM Eastern

About Climb Bio Stock (NASDAQ:CLYM)

Key Stats

Today's Range
$2.17
$2.42
50-Day Range
$1.18
$2.38
52-Week Range
$1.05
$8.79
Volume
799,762 shs
Average Volume
778,093 shs
Market Capitalization
$161.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Climb Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

CLYM MarketRank™: 

Climb Bio scored higher than 68% of companies evaluated by MarketBeat, and ranked 293rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Climb Bio has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Climb Bio has only been the subject of 3 research reports in the past 90 days.

  • Read more about Climb Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Climb Bio has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Climb Bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for CLYM.
  • Dividend Yield

    Climb Bio does not currently pay a dividend.

  • Dividend Growth

    Climb Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CLYM.
  • News Sentiment

    Climb Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Climb Bio this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for CLYM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Climb Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of Climb Bio is held by insiders.

  • Percentage Held by Institutions

    69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Climb Bio's insider trading history.
Receive CLYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.

CLYM Stock News Headlines

Climb Bio (NASDAQ:CLYM) Coverage Initiated at Robert W. Baird
Analysts Set Climb Bio, Inc. (NASDAQ:CLYM) Target Price at $9.00
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.tc pixel
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at Baird R W
What is Leerink Partnrs' Estimate for Climb Bio Q3 Earnings?
See More Headlines

CLYM Stock Analysis - Frequently Asked Questions

Climb Bio's stock was trading at $1.80 at the start of the year. Since then, CLYM stock has increased by 32.2% and is now trading at $2.38.

Climb Bio, Inc. (NASDAQ:CLYM) posted its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06.

Climb Bio's top institutional investors include Diadema Partners LP (1.04%), Nan Fung Trinity HK Ltd. (0.69%), Shay Capital LLC (0.61%) and Geode Capital Management LLC (0.46%).
View institutional ownership trends
.

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLYM
Previous Symbol
NASDAQ:CLYM
CIK
1768446
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$7.00
Potential Upside/Downside
+278.2%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.70)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.90 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-23.10%
Return on Assets
-22.47%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
14.08
Quick Ratio
14.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.74 per share
Price / Book
0.87

Miscellaneous

Outstanding Shares
67,764,000
Free Float
67,222,000
Market Cap
$161.28 million
Optionable
N/A
Beta
-0.11
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CLYM) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners